These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29468578)

  • 21. Clinical decision analysis as a means of technology assessment. The effectiveness of intraoperative cholangiography.
    Scott TE; Jacoby I
    Int J Technol Assess Health Care; 1992; 8(1):185-97. PubMed ID: 1601587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.
    Mühlbacher AC; Sadler A
    Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?
    Paulden M
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):239-242. PubMed ID: 28490259
    [No Abstract]   [Full Text] [Related]  

  • 24. Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting.
    Angelis A; Montibeller G; Hochhauser D; Kanavos P
    BMC Med Inform Decis Mak; 2017 Oct; 17(1):149. PubMed ID: 29073892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multi-criteria decision approach for ranking unmet needs in healthcare.
    Cleemput I; Devriese S; Kohn L; Westhovens R
    Health Policy; 2018 Aug; 122(8):878-884. PubMed ID: 29983193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Knowledge Translation in Practice: Exploring the Potential Use of MCDA in Central America and the Caribbean.
    Espinoza MA; Rojas R; Acosta de Patiño H
    Value Health Reg Issues; 2018 Dec; 17():148-149. PubMed ID: 30184512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Economic health technology assessment: challenges and perspectives].
    Zerda A
    Biomedica; 2014; 34(2):161-3. PubMed ID: 24967920
    [No Abstract]   [Full Text] [Related]  

  • 28. High-cost, high-tech medicine: are we getting our money's worth?
    Tuman KJ; Ivankovich AD
    J Clin Anesth; 1993; 5(2):168-77. PubMed ID: 8476624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economics meets healthcare: how can it be useful?
    Barros PP
    Eur J Cardiothorac Surg; 2018 Jul; 54(1):1-3. PubMed ID: 29733425
    [No Abstract]   [Full Text] [Related]  

  • 30. Net clinical benefit: the art and science of jointly estimating benefits and risks of medical treatment.
    Towse A
    Value Health; 2010 Jun; 13 Suppl 1():S30-2. PubMed ID: 20618793
    [No Abstract]   [Full Text] [Related]  

  • 31. An introduction to the methods of cost-effectiveness analysis.
    Drug Ther Bull; 2012 Jul; 50(7):81-4. PubMed ID: 22789768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prioritisation of specialist health care services; not NICE, not easy but it can be done.
    Anderson P; Webb P; Groves S
    Health Policy; 2017 Sep; 121(9):978-985. PubMed ID: 28797706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The need for independent physics advice.
    Bergmann H
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):491-3. PubMed ID: 12785357
    [No Abstract]   [Full Text] [Related]  

  • 34. Objectivity and equity: clarity required. A response to Hill and Olson.
    Paulden M; O'Mahony JF; Culyer AJ; McCabe C
    Pharmacoeconomics; 2014 Dec; 32(12):1249-50. PubMed ID: 25412736
    [No Abstract]   [Full Text] [Related]  

  • 35. Why it's Time to Abandon the ICER.
    Paulden M
    Pharmacoeconomics; 2020 Aug; 38(8):781-784. PubMed ID: 32390066
    [No Abstract]   [Full Text] [Related]  

  • 36. Health economic evaluations using decision analytic modeling. Principles and practices--utilization of a checklist to their development and appraisal.
    Soto J
    Int J Technol Assess Health Care; 2002; 18(1):94-111. PubMed ID: 11987445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporating option values into the economic evaluation of health care technologies.
    Palmer S; Smith PC
    J Health Econ; 2000 Sep; 19(5):755-66. PubMed ID: 11184803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Care to compare?
    Aston G
    Hosp Health Netw; 2008 Dec; 82(12):38-41, 1. PubMed ID: 19209502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of model inputs and assumptions in conducting health technology assessments of novel drugs.
    Philipson T; MacEwan JP
    J Med Econ; 2017 Oct; 20(10):1107-1109. PubMed ID: 28737052
    [No Abstract]   [Full Text] [Related]  

  • 40. Problems of using modelling in the economic evaluation of health care.
    Sheldon TA
    Health Econ; 1996; 5(1):1-11. PubMed ID: 8653188
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.